Overview
Fabino Enterprises Limited is primarily engaged in the manufacturing and marketing of pharmaceutical, allopathic, herbal, and veterinary products under its own brand names, targeting both domestic and international markets.
Fabino's operations include a manufacturing plant in Sonipat, Haryana, and it markets over 70 products in the domestic market, along with a diverse portfolio of FMCG products for international markets.
The company has achieved ISO 9001:2015 certification, reflecting its commitment to high-quality standards in manufacturing processes and quality management systems.
Fabino Enterprises has expanded its scope to include agriculture-related products and activities, as well as food processing and exports, highlighting a strategic diversification into the agriculture sector.
The company IPO in January 2022 reflected strategic growth initiatives, raising funds to diversify its operations with a focus on FMCG and wellness sectors.
- Sector
Pharmaceuticals
- Industry
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
- Market Cap
3 Cr
- Volatility
Low Risk
- P/E Ratio
45.2
- Industry P/E
28.0
- PEG Ratio
1.1
- P/B Ratio
0.7
- 52W High
38.96
- 52W Low
13.01
Financial Ratios
Sales CAGR
- 1Y
- -14.42%
- 3Y
- 62.53%
- 5Y
- 19.13%
- 10Y
- —
Profit CAGR
- 1Y
- 50.00%
- 3Y
- 41.03%
- 5Y
- 13.87%
- 10Y
- —
ROE
- TTM
- -3.80%
- 3Y
- 1.52%
- 5Y
- 1.49%
- 10Y
- —
ROCE
- TTM
- 2.09%
- 3Y
- 3.13%
- 5Y
- 2.82%
- 10Y
- —
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI
